

**UNITED STATES INTERNATIONAL TRADE COMMISSION**  
**Washington, D.C.**

**In the Matter of**

**CERTAIN OVER-THE-COUNTER  
TOPICAL LIDOCAINE PATCHES**

**Investigation No. 337-TA-1498**

**NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL  
DETERMINATION SETTING AN 18-MONTH TARGET DATE**

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (“ID”) (Order No. 5) of the presiding chief administrative law judge (“CALJ”) setting an 18-month target date of October 14, 2027, for completion of the above-captioned investigation.

**FOR FURTHER INFORMATION CONTACT:** Richard P. Hadorn, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C. 20436, telephone (202) 205-3179. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on April 14, 2026, based on a complaint filed by J.A.R. Laboratories LLC of Lake Forest, Illinois. 91 FR 19203 (Apr. 14, 2026). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based on the importation into the United States, the sale for importation, and the sale within the United States after importation of certain over-the-counter topical lidocaine patches by reason of the infringement of certain claims of U.S. Patent No. 12,109,181. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The notice of investigation names 13 respondents: Veridian Healthcare LLC of Gurnee, Illinois; Perrigo Company plc of Dublin, Ireland; Perrigo Company of Allergan, Michigan; Perrigo Direct, Inc. of Peachtree City, Georgia; Opella Healthcare Group SAS of Neuilly-sur-Seine, France; Opella North America of Morristown, New Jersey; Chattem, Inc. of Chattanooga, Tennessee; Hisamitsu Pharmaceutical Co., Inc. of Tosu, Japan; Hisamitsu U.S., Inc. of Florham, New Jersey; Hisamitsu America, Inc. of Florham, New Jersey; Reckitt Benckiser Group PL of

Slough, United Kingdom; Reckitt Benckiser LLC of Parsippany, New Jersey; and RB Health LLC of Parsippany, New Jersey. *Id.* The Office of Unfair Import Investigations is not named as a party. *Id.*

On May 27, 2026, the CALJ issued the subject ID (Order No. 5) setting an 18-month target date of October 14, 2027, for completion of the investigation. The subject ID states that the final ID is due no later than June 14, 2027. No petitions for review of the subject ID were filed.

The Commission has determined not to review the subject ID. The target date for completion of the investigation is October 14, 2027.

The Commission vote for this determination took place on June 24, 2026.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read 'Lisa R. Barton', enclosed within a large, loopy oval shape.

Lisa R. Barton  
Secretary to the Commission

Issued: June 24, 2026